| Patient | Zelda Fitzgerald |
|---|---|
| Date of birth | 1900-07-24 |
| Identifiers | MRN HR-ET004-SYN-TD; SSN (made up) 000-04-8712 |
| Document date | 1930-06-08 |
| Author | Margot Ellery, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Lithium level after the sick visit, prolactin, and the antipsychotic plan. [S]
Ms. Fitzgerald returns one week after the sick visit for gastroenteritis, when her lithium level was 1.4 mmol/L. She held lithium for two days as advised, was eating and drinking normally by the third day, and restarted 300 mg twice daily five days ago. The diarrhea stopped within four days. Her tremor is back to a faint shake when she is tired. She admits that she did not go for the lithium level that was due a week after starting, because she felt well and forgot. Her mood is better, and she has had no manic or psychotic symptoms. She saw the sports dietitian and is eating three meals and two snacks; she has started one gentle class a day. Her periods have not returned. She has had no thoughts of suicide or self-harm. [S]
| Element | Detail |
|---|---|
| Lithium | Held two days, restarted five days ago at 300 mg twice daily |
| Gastroenteritis | Resolved |
| Mood | Better; PHQ-9 7; item 9 scored 0 |
| Periods | Still absent |
| Food and dance | Three meals and two snacks; one gentle class a day |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | Diarrhea and vomiting resolved; eating normally |
| Genitourinary | Positive | No periods; no increased urination |
| Neurological | Negative | Faint tremor only when tired; no unsteadiness or confusion |
| Psychiatric | Negative | Mood better; no manic or psychotic symptoms; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Risperidone 2 mg oral tablet, one tablet by mouth at bedtime (started in hospital) | One tablet by mouth at bedtime | Oral route | 1930-04-20 to 1930-06-08 | completed | S |
| Lithium carbonate 300 mg oral capsule, one capsule by mouth twice daily | One capsule by mouth twice daily | Oral route | 1930-05-18 | active | S |
| Risperidone 1 mg oral tablet, one tablet by mouth at bedtime for one week, then stop | One tablet by mouth at bedtime for one week | Oral route | 1930-06-08 to 1930-06-15 | completed | S |
| Aripiprazole 10 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 1930-06-08 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1930-06-08 | Body height | 165 | cm | S |
| 1930-06-08 | Body weight | 50.2 | kg | S |
| 1930-06-08 | Body mass index (BMI) [Ratio] | 18.4 | kg/m2 | S |
| 1930-06-08 | Systolic blood pressure | 104 | mm[Hg] | S |
| 1930-06-08 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1930-06-08 | Heart rate | 74 | /min | S |
| 1930-06-08 | Respiratory rate | 14 | /min | S |
| 1930-06-08 | Body temperature | 36.6 | Cel | S |
| 1930-06-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1930-06-08 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1930-06-08 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1930-06-08 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1930-06-08 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1925)/1.73 sq M | 105 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1930-06-08 | Lithium [Moles/volume] in Serum or Plasma | 0.8 | mmol/L | Maintenance target 0.6 to 0.8 mmol/L; above 1.2 mmol/L is above the therapeutic range | Normal | S |
| 1930-06-08 | Prolactin [Mass/volume] in Serum or Plasma | 66 | ng/mL | 4.8-23.3 ng/mL | High | S |
| 1930-06-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S |
Vital signs recorded on 1930-06-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and well hydrated; weight 50.2 kg; blood pressure 104/66, pulse 74 |
| Neurological | Very faint fine postural tremor; no ataxia; no akathisia or rigidity |
| Psychiatric | Brighter; organized; no psychotic or manic features |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First episode of psychosis with marked mood symptoms: about three weeks of little sleep, rapid speech, racing thoughts, grandiose plans and very long training days, then a voice commenting on her dancing and a belief that she was being watched and tested; tearful low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, schizoaffective disorder (bipolar type), and schizophreniform disorder or schizophrenia, depending on whether the psychosis ever occurred apart from the mood symptoms. Synthetic modern episode linked to her documented first hospitalization | active | provisional | F29 | S — Synthetic modern coding of the documented first breakdown. Unspecified psychosis is coded until the course shows how the psychosis relates to the mood symptoms; superseded at the three-month visit. |
| Secondary amenorrhea: no periods for about four months before admission, during very heavy dance training at a low weight (BMI 18.7), with prolactin raised on risperidone; pregnancy test negative | active | confirmed | N91.1 | S — Synthetic presenting finding linked to her documented training; resolved when her periods returned. |
| Acute viral gastroenteritis (vomiting and watery diarrhea for two days, roommate with the same illness), with mild dehydration; resolved | resolved | confirmed | A08.4 | S — Synthetic acute infection; not a historical claim. |
| Lithium level above the therapeutic range (1.4 mmol/L) during dehydration, with nausea and a worse fine tremor, without confusion or unsteadiness; lithium held and restarted; resolved | resolved | confirmed | T43.595A | S — Synthetic medication adverse effect at a prescribed dose; ICD-10-CM classifies lithium salts with the other antipsychotics and neuroleptics. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Risperidone 2 mg; switching to aripiprazole 10 mg with a one-week taper |
| Survey | Manic, depressive, and psychotic symptoms, and early warning signs | Every visit | Completed today | No manic, depressive-episode, or psychotic symptoms |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | None; to be checked during the switch |
| Examination | Weight and BMI | Every visit for 6 months after starting or changing an antipsychotic (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 50.2 kg, down 0.8 kg after the gastroenteritis |
| Laboratory | Prolactin | When there are symptoms of high prolactin, such as missed periods | Completed today | 66 ng/mL, still raised, with absent periods; antipsychotic switched |
| Laboratory | Lithium level (12-hour trough) | 5 to 7 days after starting and after any change until stable, then every 3 to 6 months | Deferred | The level due 5 to 7 days after starting was not drawn: she felt well and missed the laboratory visit. The first level was at the sick visit (1.4 mmol/L, raised by dehydration, not by the dose). Today 0.8 mmol/L, five days after restarting. Corrective action: the care coordinator sends a reminder before each laboratory test |
| Laboratory | Creatinine and eGFR on lithium | Baseline, every 2 to 3 months for 6 months, then every 6 to 12 months | Completed today | Creatinine 0.78 mg/dL, eGFR 105, back from 1.08 at the sick visit; sodium 139, potassium 4.1 mmol/L |
| Laboratory | TSH on lithium | Baseline, once or twice in the first 6 months, then every 6 to 12 months | Up to date | Baseline normal; next at three months |
| Medication safety | Lithium side effects and sick-day rules | At the start and every visit | Completed today | Faint tremor only; sick-day plan in her phone |
| Medication safety | Pregnancy prevention on lithium; valproate avoided | Before starting and at each visit until a reliable method is in place | Completed today | Condoms used; long-acting methods discussed; she will decide at the preventive visit |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 7, item 9 scored 0 |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan current; the 988 Suicide & Crisis Lifeline in her phone |
| Self-management | Sleep | Every visit | Completed today | Eight or nine hours |
| Self-management | Eating, exercise, and periods | Every visit while periods are absent or weight is low | Completed today | Dietitian plan of three meals and two snacks; one gentle class a day; periods absent |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Care coordinator weekly; therapist started |
Goal progress:
Guideline basis: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence (2023); The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Three-month visit in nine weeks, fasting, with lithium level, kidney and thyroid tests, calcium, prolactin, glucose, A1c, and lipids. Care coordinator weekly. Next scheduled visit 1930-08-10: three-month review: lithium, thyroid, kidney and metabolic checks, and the diagnosis reviewed. [S]